Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A matching-adjusted indirect comparison (MAIC) of zanubrutinib vs venetoclax + ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL)

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTalha MunirLMLeyla Mohseninejad

Discussion

Loading...

Member takes

Overview

MAIC shows improved progression-free survival with zanubrutinib vs venetoclax + ibrutinib in chronic lymphocytic leukemia, suggesting better outcomes overall.

Key Points

  • Zanubrutinib showed a clinical advantage in progression-free survival compared to venetoclax + ibrutinib in chronic lymphocytic leukemia.
  • An unadjusted hazard ratio of 0.49 indicates a significant treatment benefit for zanubrutinib over the compared regimen.
  • MAIC procedures helped address population differences in chronic lymphocytic leukemia efficacy outcomes between studies.
  • These findings underscore the potential for zanubrutinib to enhance treatment results in treatment-naive patients with CLL.

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6b3https://doi.org/10.1182/blood-2025-7436
View Full Paper
Ask AI
Bookmark
Share